BlackRock · Q2 2026 · Published 15 May 2026 · Essay or commentary
Seeking Innovation Beyond Tech? Insight on Healthcare Stocks
Carrie King and Erin Xie argue that healthcare stocks, trading at a 16% discount to the market after 89% of S&P 500 healthcare companies beat 2025 earnings estimates, offer AI-driven innovation with low correlation to technology.
Summary
Carrie King, Global CIO of BlackRock Fundamental Equities, and Erin Xie, head of its Health Sciences team, answer five questions about healthcare stocks. They describe how the FDA and federal agencies opened the way for AI in drug research and medical devices. They argue that healthcare is defensive, cheap relative to the market and only loosely correlated with technology. They expect policy risks from tariffs, the One Big Beautiful Bill Act and Most Favored Nation drug pricing to fade, and they favour active stock selection because returns within the sector differ widely.
Key insights
- The FDA cleared six AI medical devices in 2015 and 331 in 2025, a total of 1,394 since 2015, with radiology and diagnostics making up 77% of clearances.
- 89% of S&P 500 healthcare companies beat earnings expectations in the four quarters of 2025, second among all sectors.
- Healthcare trades at a 16% discount to the market on forward earnings after historically trading at a premium.
- 17 global pharmaceutical companies have reached drug-pricing agreements with the U.S. administration.
- In 2025 biotech rose 33% while healthcare services and providers fell 7%.
- S&P Global Market Intelligence projects that people older than 65 will be 20% of the U.S. population by 2030.
Quotes
The proportion of the U.S. population older than 65 is projected to reach 20% by 2030, according to S&P Global Market Intelligence.Show at the source ↗
More